drugset / Trial / NCT02186171

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis

NCT02186171

Phase 3 Completed 245 enrolled Amgen
RandomizedParallel-groupTriple-blindTreatment

Summary

The study is designed to evaluate if treatment with romosozumab once a month for 12 months compared with placebo is effective in increasing bone mineral density (BMD) at the lumbar spine. Additionally, the study will assess the effect of treatment with romosozumab for 12 months compared with placebo on BMD at the femoral neck and total hip.

Timeline

Start
2014-06-16
Primary completion
2016-02-15
Completion
2016-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Romosozumab Monoclonal antibody 210 mg Subcutaneous

Indications